跳至主要内容
临床试验/CTRI/2012/01/002377
CTRI/2012/01/002377招募中2 期

Clinical Evaluation of Vyoshadi Guggulu and Haritaki Churna in the Management of Obesity (Sthaulya) - ACT- OB-2010

Department of AYUSH Ministry of Health Family Welfare Government of India0 个研究点目标入组 150 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Patients of either sex with age between 18 and 65 years.
  • 2. BMI >=30 kg/m2 and < 40 kg/m2
  • 3. Willing and able to participate in the study for 16 weeks.

排除标准

  • 1. Intake of over the counter weight loss agents, centrally acting appetite suppressants in
  • the previous six months.
  • 2. Pathophysiologic/ genetic syndromes associated with obesity (Cushingâ??s syndrome,
  • Turnerâ??s syndrome, Prader willi syndrome).
  • 3. Patients with evidence of malignancy
  • 4. Patients with poorly controlled Diabetes Mellitus (HbA1c > 10%)
  • 5. Patients with poorly controlled Hypertension ( > 160 / 100 mm Hg)
  • 6. Patients on prolonged ( > 6 weeks) medication with corticosteoids, antidepressants,
  • anticholinergics, etc. or any other drugs that may have an influence on the outcome of
  • 7. Patients suffering from major systemic illness necessitating long term drug treatment
  • (Rheumatoid arthritis, Tuberculosis, Psycho-Neuro-Endocrinal disorders, etc.)
  • 8. Patients who have a past history of Atrial Fibrillation, Acute Coronary Syndrome,
  • Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months.
  • 9. Symptomatic patient with clinical evidence of Heart failure.
  • 10. Patients with concurrent serious hepatic disorder (defined as Aspartate Amino
  • Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin,
  • Alkaline Phosphatase (ALP) > 2 times upper normal limit) or Renal Disorders
  • (defined as S. Creatinine >1.2mg/dL), Severe Pulmonary Dysfunction (uncontrolled
  • Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]), or any
  • other condition that may jeopardize the study.
  • 11. Alcoholics and/or drug abusers.
  • 12. Prior surgical therapy for obesity
  • 13. H/o hypersensitivity to any of the trial drugs or their ingredients.
  • 14. Pregnant / lactating woman.
  • 15. Patients who have completed participation in any other clinical trial during the past
  • six (06) months.
  • 16. Any other condition which the Principal Investigator thinks may jeopardize the study.

研究者

发起方
Department of AYUSH Ministry of Health Family Welfare Government of India

相似试验